Allogene Therapeutics, Inc.
ALLO
$1.21
-$0.01-0.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 23.23% | 8.10% | 30.12% | -6.43% | 16.25% |
| Total Depreciation and Amortization | -14.76% | -12.83% | -7.02% | -10.22% | 0.03% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -36.94% | 7.17% | -56.22% | 23.87% | -3.20% |
| Change in Net Operating Assets | 87.84% | -46.80% | 203.90% | 54.00% | -321.79% |
| Cash from Operations | 38.62% | 5.31% | 31.67% | 20.56% | -2.80% |
| Capital Expenditure | -- | -1,137.50% | -41.99% | -3,475.00% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -41.19% | -71.66% | -18.41% | -120.59% | 327.63% |
| Cash from Investing | -41.25% | -72.10% | -18.57% | -121.76% | 334.81% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.58% | 544.85% | 3,605.16% | -84.15% | 18.76% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 56.05% | -- | -- | -- | -- |
| Cash from Financing | -95.33% | 747.88% | 3,605.16% | -84.15% | 21.31% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -91.74% | -2.01% | 72.40% | -39.66% | 166.87% |